To succeed, an emerging biotech firm must maximize the value of its therapeutic assets as they move through development and hopefully to market. It typically realizes that value through a series of transactions with investors and/or partners. This paper outlines the need for a strong commercial proposition for an asset, even early in the process, to support a strong valuation. It then provides guidance on how to develop and communicate a strong commercial proposition.
Want to Join Our Team?
Learn about Blue Matter's innovative work experiences, enriching development opportunities, team-oriented "People First" culture, and a lot more.
